#Canada #Vancouver #biopharmaceuticals #BioVaxys #MCTO Update

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

BioVaxys Technology Corp., a burgeoning player in the biopharmaceutical field, has recently issued its bi-weekly update regarding the status of the management cease trade order (MCTO) imposed by the British Columbia Securities Commission (BCSC). This action, which took effect on March 3, 2025, comes as a consequence of the company's inability to file its audited annual financial statements for the fiscal year ending October 31, 2024.

The core of the matter stems from BioVaxys's announcement made on February 13 and again on March 3, where the company revealed its struggle to file essential documents including its annual financial statements and accompanying management discussion and analysis by the February 28 deadline mandated under National Instrument 51-102.

Current Efforts and Projections

In light of these developments, BioVaxys is actively collaborating with its auditing firm, Dale Matheson Carr-Hilton LaBonte LLP, to ensure all required filings are completed promptly. The company has expressed confidence in its ability to meet the March 30 deadline for these filings, provided that no significant changes occur within their operational circumstances.

As part of its commitment to transparency, BioVaxys has confirmed several important details:
1. The company intends to continue fulfilling the alternative information guidelines under NP 12-203 by releasing bi-weekly updates to keep the investing public informed during the ongoing default situation.
2. As of the current update, BioVaxys does not foresee any anticipated defaults beyond the current situation regarding the filing delays.
3. The company is not undergoing any insolvency proceedings.
4. No other material information regarding the company's affairs remains undisclosed.

During the effective period of the MCTO, while there are restrictions placed on the company’s executives concerning trading shares, the general public will still have the freedom to trade BioVaxys's shares without any limitations. This stipulation appears designed to maintain investor confidence while the company works diligently to rectify its filing obligations.

About BioVaxys Technology Corp.

Established in British Columbia, BioVaxys Technology Corp. is dedicated to innovative therapeutics, leveraging its proprietary DPX™ immune-educating technology platform and the HapTenix© neoantigen tumor cell construct platform to combat diseases such as cancers and autoimmune conditions. Its current clinical pipeline includes promising candidates like maveropepimut-S, which is undergoing Phase II trials for treating advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer. Furthermore, the BVX-0918 personalized immunotherapeutic vaccine is poised to enter Phase I trials in Spain, focusing on late-stage ovarian cancer treatments.

BioVaxys is also making strides in tumor immunology, deriving valuable insights and a distinctive library of T-lymphocytes from its personalized vaccinations, aiming to enhance the predictability of emerging targetable tumor antigens.

For anyone interested in the latest updates or more information about BioVaxys, the company actively engages with its audience via its website at www.biovaxys.com and maintains a presence on social media platforms such as X and LinkedIn.

In conclusion, while the road ahead may present challenges, BioVaxys Technology Corp. is poised to navigate these hurdles while maintaining transparency with its stakeholders. The next update will be awaited by its investors and involved parties as they look toward a successful resolution of the MCTO.